JCOG

The Japan Clinical Oncology Group (JCOG) is the largest Japanese cooperative group funded primarily by the National Cancer Center Research and Development Fund.

LCSSG:Lung Cancer Surgical Study Group / Publications

更新日:2008年12月26日

a. 論文

1. 委員会承認の治療研究

JCOG8601
M Ohta, R Tsuchiya, M Shimoyama, et al.: Adjuvant Chemotherapy for Completely Resected Stage III Non-small-cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery. 106(4): 703-708, 1993.
JCOG 9101
R Tsuchiya, K Suzuki, Y Ichinose, et al.: Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 129(5): 977-983, 2005.
JCOG9209
K Nagai, R Tsuchiya, et al.: A Randomized Trial Comparing Induction Chemotherapy Followed by Surgery with Surgery Alone for Patients with Stage ⅢA N2 Non-Small Cell Lung Cancer (JCOG 9209). J Thorac Cardiovasc Surg. 125(2): 253-260, 2003.
JCOG 9304
H Tada, R Tsuchiya, Y Ichinose, et al.: A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43(2): 167-173, 2004.

2. グループ代表者管理の治療研究

  • Y Ichinose, T Yano, H Asoh, et al.: Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis. J Surg Oncol. 66: 196-200, 1997.
  • Y Ichinose, T Yano, S Kudoh, et al.: A phase II trial UFT plus cisplatin in advanced non-small-cell lung cancer: Interim analysis of 67 patients. Oncology. 11(S): 103-105, 1997.
  • M Sato, T Koike, K Yokoi, et al.: Second operation for upper mediastinal lymphadenopathy after complete resection for cancer of the left lung. J Thorac Cardiovasc Surg. 119(6): 1291-1292, 2000.
  • Y Ichinose, R Tsuchiya, T Koike, et al.: The prognosis of patients with non-small cell lung cancer found to have carcinomatous pleuritis at thoracotomy. Surgery Today. 30:1062-1066, 2000.
  • K Yokoi, R Tsuchiya, et al.: Results of surgical treatment of lung cancer involving the diaphragm. J Thorac Cardiovasc Surg. 120(4): 799-805, 2000.
  • M Sagawa, T Koike, M Sato, et al.: Segmentectomy for roentgenographically occult bronchogenic squamous cell carcinoma. Ann Thorac Surg. 71: 1100-1104, 2001.
  • Y Ichinose, R Tsuchiya, T Yasumitsu, et al.: Prognosis of non-small cell lung cancer patients with positive pleural lavage cytology after a thoracotomy: results of the survey conducted by the Japan Clinical Oncology Group. Lung Cancer. 31: 37-41, 2001.
  • Y Ichinose, R Tsuchiya, T Koike, et al. and the Japan Clinical Oncology Group: Prognosis of Resected Non-Small Cell Lung Cancer Patients with Carcinomatous Pleuritis of Minimal Disease. Lung Cancer. 32: 55-60, 2001.
  • Y Ichinose, H Kato, T Koike, et al. and the Japan Clinical Oncology Group: Overall Survival and Local Recurrence of 406 Completely Resected Stage IIIa-N2 Non-Small Cell Lung Cancer Patients: Questionnaire Survey of the Japan Clinical Oncology Group to Plan for Clinical Trials. Lung Cancer. 34: 29-36, 2001.
  • Y Ichinose, H Kato, T Koike, et al. and The Japan Clinical Oncology Group: Completely Resected Stage IIIA Non-Small Cell Lung Cancer: The significance of Primary Tumor Location and N2 Station. J Thorac Cardiovasc Surg. 122: 803-808, 2001.
  • T Osaki, T Oyama, M Inoue, et al.: Molecular biological markers and micrometastasis in resected non-small- cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg. 49(9): 545-551, 2001.
  • Y Ichinose, R Tsuchiya, T Koike, et al.: A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: The incidence of carcinomatous pleuritis after surgical intervention. J Thorac Cardiovasc Surg. 123: 695-699, 2002.
  • M Sagawa, M Sato, T Kondo, et al.: A Prospective Trial of Systematic Nodal Dissection for Lung Cancer by Video-Assiste Thoracic Surgery: Can It Be Perfect? The Annals of Thoracic Surgery. 73(3): 900-904, 2002.
  • C Endo, Y Saito, T Kondo, et al.: A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer. 40: 181-186, 2003.
  • H Kato, Y Ichinose, et al.: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 350(17): 1713-1721, 2004.
  • 星川 康、近藤 丘:肺切除後の特発性肺線維症急性増悪及び急性間質性肺炎について. 日本外科学会雑誌. 105(12): 757-762, 2004.
  • T Mitsudomi, T Kosaka, H Endoh, et al.: Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients with Non-Small-Cell Lung Cancer With Postoperative Recurrence. J Clin Oncol. 23:2513-20, 2005.
  • 千田雅之、高橋博人、山中秀樹、他:限局性間質性肺炎からの肺癌手術後急性増悪例の検討.胸部外科58(1): 22-25, 2005.
  • M Tsuboi, H Kato, K Nagai, et al.: Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs. 16(10): 1123-1128, 2005.

3. 附随研究等

  • Y Ichinose, T Yano, H Asoh, et al.: Diagnosis of visceral pleural invasion in resected lung cancer using a jet stream of saline solution. Ann Thorac Surg. 64: 1626-1629, 1997.
  • Y Fukuyama, T Mitsudomi, K Sugio, et al.: K-ras and p53 mutations are on independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Be J Cancer. 75: 1125-1130, 1997.
  • H Saito, M Taniguchi, T Fukasawa, et al.: Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer. Cancer Immunol Immunother. 44: 83-87, 1997.
  • T Fujisawa, Y Yamaguchi: Autologous tumor killing activity as a prognostic factor in primary resected non-small cell carcinoma of the lung. Cancer. 79: 474-481, 1997.
  • T Yano, Y Fukuyama, H Yokoyama, et al.: HLA class I and class II expression of pulmonary adenocarcinoma cells and the influence of interferon gamma. Lung Cancer. 20: 185-190, 1998.
  • T Yano, Y Fukuyama, H Yokoyama, et al.: Long-term survivors with pN2 non-small cell lung cancer after a complete resection with a systemic mediastinal node dissection. Eur J Cardio-thorac Surgery. 14: 152-155, 1998.
  • T Kondo, M Sagawa, T Tanita, et al.: Is complete systematic nodal dissection by thoracoscopic surgery possible? ? a prospective trial of video-assisted lobectomy for cancer of the right lung. J Thorac Cardiovasc Surg. 116: 651-652, 1998.
  • C Endo, M Sagawa, M Sato, et al.: What kind of hilar lung cancer can be a candidate for segmentectomy with curative intent?: retrospective clinicopathological study of completely resected roentgenographically occult bronchogenic squamous cell carcinoma. Lung Cancer. 21: 93-97, 1998.
  • M Sato, A Sakurada, M Sagawa, et al.: Chromosome bands 3p14.2, 9p21, and 13p14 are frequently deleted in roentgenographically occult bronchogenic squamous cell carcinoma of the lung. Genes Chromosomes Cancer. 23: 367-370, 1998.
  • K Inoue, M Sato, S Fujimura, et al.: Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg. 116: 407-411, 1998.
  • M Sagawa, Y Saito, S Fujimura, et al.: K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer. Brit J Cancer. 77: 720-723, 1998.
  • T Iizasa, T Fujisawa, Y Saitoh, et al.: Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma. Cancer Immunol Immunother. 46: 345-349, 1998.
  • M Murata, M Tagawa, H Kimura, et al.: Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol. 12: 577-581, 1998.
  • K Hirashima, T Toyozaki, H Kohno, et al.: Synchronous and metachronous lung carcinomas: Molecular evidence for multicentricity. Pathology International. 48: 869-876, 1998.
  • C Konaka, N Ikeda, T Hiyoshi, et al.: Peripheral non-small cell Lung cancers 2.0 cm or less in diameter: Proposed criteria for limited pulmonary resection based upon clinicopathological presentation. Lung Cancer. 21: 185-191, 1998.
  • H Nakamura, N Kawasaki, M Hagiwara et al.: Clinical features of long-surviving lung cancer patients without resection. Ann Cancer Res Ther. 7: 25-28, 1998.
  • H Miura, O Taira, O Uchida, et al.: Invasion to Interlobar Pleura and Beyond in Non-small Cell Lung Cancer. Chest. 114: 1301-1304, 1998.
  • H Miura, H Nakamura, O Taira, et al.: Outcome of Patients with early Stage Lung Cancer. Surg Today. 28: 736-739, 1998.
  • H Miura, O Taira, S Hiraguri, et al.: Cavitating Adenocarcinoma of the Lung. Ann Thorac Cardiovasc Surg 4: 154-158, 1998.
  • M Sato, Y Saito, S Fujimura, et al.: Involvement of the #12u lymph nodes around the upper lobe bronchi in patients with lung cancer of the right middle lobe, right lower lobe, or left lower lobe. Surg Today. 29: 238-242, 1999.
  • M Sagawa, A Sakurada, S Fujimura, et al.: Five-year survivors with resected pN2 non-small cell lung carcinoma. Cancer. 85: 864-868, 1999.
  • R Yamamoto, H Tada, A Kishi, et al.: Effects of preoperative chemotherapy and radiation therapy on human bronchial blood flow. The Journal of Thoracic and Cardiovascular Surgery. 119(5): 939-945, 2000.
  • H Nakamura, H Kato, C Konaka, et al.: Cellular immunologic parameters related to age, gender, and stage in lung cancer. Lung Cancer. 28: 139-145, 2000.
  • J Usuda, N Saijo, H Kato, et al.: Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. International Journal of Cancer. 85: 275-283, 2000.
  • H Asamura, R Tsuchiya, et al.: Where is the boundary between N1 and N2 stations in lung cancer? : A prognostic significance of N1 lymph node metastasis. Ann. Thorac. Surg 2000. 70: 1839-1846, 2000.
  • H Nakamura, N Kawasaki, M Hagiwara, et al.: Endoscopic evalution of centrally located squamous cell carcinoma of the lung. Cancer. 91: 1142-1147, 2001.
  • J Usuda, T Okunaka, K Furukawa, et al.: Increased cytotoxic effects of photodynamic therapy in IL-6 gene transfected cells via enhanced apoptosis. Int J Cancer. Aug. 15; 93(4): 475-80, 2001.
  • H Nakamura, N Kawasaki, M Hagiwara, et al.: Early hilar lung cancer-risk for multiple lung cancers and clinical outcome. Lung Cancer. 33: 51-57, 2001.
  • T Takezaki, K Hirose, M Inoue, et al.: Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas. Br J Cancer. 84(9): 1199-1206, 2001.
  • Y Shou, T Hirano, Y Gong, et al.: Influence of angiogenesis factors and matrix metalloproteinases upon tumour prognosis in non-small cell lung cancer. Br J Cancer. 85(11): 1706-12, 2001.
  • E Nakajima, T Hirano, C Konaka, et al.: K-ras mutation in sputum of primary lung cancer patients does not always reflect that of cancerous cells. Int J Oncol. 18(1): 105-10, 2001.
  • N Haruki, T Harano, A Masuda, et al.: Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am J Pathol. 159(4): 1345-1352, 2001.
  • T Sobue, N Moriyama, M Kaneko, et al.: Screening for Lung Cancer With Low-Dose Helical Computed Tomography: Anti-Lung Cancer Association Project. J Clin Oncol. 20(4): 911-920, 2002.
  • J Tsurutani, T Komiya, H Uejima, et al.: Mutational analysis of the β-tubulin gene in lung cancer. Lung Cancer. 35(1): 11-16, 2002.
  • J Tsurutani, T Nitta, T Hirashima, et al.: Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer. 35(3): 299-304, 2002.
  • Y Ichinose, R Tsuchiya, T Koike, et al.: A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: The incidence of carcinomatous pleuritis after surgical intervention. The Journal of Thorac and Cardiovasc Surgery. 123: 695-699, 2002.
  • Y Ichinose, K Genka, T Koike, et al.: Randomized Double-Blind Placebo-Controlled Trial of Bestatin and Patients with Resected, Stage I Squamous-Cell Lung Carcinoma. J Natl Cancer Inst 95: 605-610, 2003.
  • Y Ichinose, Y Fukuyama, H Asoh, et al.: Induction Chemoradiotherapy and Surgical Resection for Selected Stage IIIB Non-Small Cell Lung Cancer. Ann Thorac Surg. 76(6): 1810-1814, 2003.
  • K Hazama, S Miyoshi, A Akashi, et al.: Clinicopathological investigation of 20 cases of primaty tracheal cancer. European Journal of Cardio-thoracic Surgery. 23: 1-5, 2003.
  • H Asamura, T Naruke, R Tsuchiya, et al.: Bronchopleural fistulas associated with lung cancer operations. Univariate and multivariate analysis of risk factors, management, and outcome. J Thorac Cardiovasc Surg. 104(5): 1456-64, 1992.
  • H Asamura, T Goya, T Naruke, et al.: Closure of fenestra in Clagett procedure: use of rectus abdominis musculocutaneous flap. Ann Thorac Surg. 54(1): 147-9, 1992.
  • H Asamura, T Naruke, R Tsuchiya, et al.: What are the risk factors for arrhythmias after thoracic operations? A retrospective multivariate analysis of 267 consecutive thoracic operations. J Thorac Cardiovasc Surg. 106(6): 1104-10, 1993.
  • H Asamura, H Kondo, T Naruke, et al.: Computed tomography-guided coil injection and thoracoscopic pulmonary resection under roentgenographic fluoroscopy. Ann Thorac Surg. 58(5): 1542-4, 1994.
  • R Tsuchiya, H Asamura, H Kondo, et al.: Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg. 57(4): 960-5, 1994.
  • H Asamura, R Tsuchiya, T Goya, et al.: Malignant germ cell tumor of the mediastinum: a multimodality therapeutic approach. Surg Today 24(2): 137-41, 1994.
  • H Asamura, H Nakayama, H Kondo, et al.: Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg. 111(6): 1125-34, 1996.
  • H Asamura, H Nakayama, H Kondo, et al.: AFP-producing squamous cell carcinoma of the lung in an adolescent. Jpn J Clin Oncol. 26(2): 103-6, 1996.
  • H Asamura, H Nakayama, H Kondo, et al.: Video-assisted lobectomy in the elderly. Chest. 111(4): 1101-5, 1997.
  • H Asamura, H Nakayama, H Kondo, et al.: Is lymph node dissection necessary in small, non-small-cell carcinoma of the lung occurring at the peripheral region?. Nippon Kyobu Geka Gakkai Zasshi. 45(3): 365-6, 1997.
  • H Asamura, H Nakayama, H Kondo, et al.: Thoracoscopic evaluation of histologically/cytologically proven or suspected lung cancer: a VATS exploration. Lung Cancer. 16(2-3): 183-90, 1997.
  • K Suzuki, K Nagai, J Yoshida, et al.: The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well- differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer. 79(8): 1521-6, 1997.
  • H Asamura, H Nakayama, H Kondo, et al.: Lobe-specific intercostal strategy in video-assisted lobectomy. Surg Laparosc Endosc. 8(1):5-8, 1998.
  • K Suzuki, N Moriyama, T Yokose, et al.: Preliminary study of percutaneous alcohol injection into the lung. Jpn J Cancer Res. 89(1): 89-95, 1998.
  • K Suzuki, T Ogura, T Yokose, et al.: Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int J Cancer. 79(4): 384-9, 1998.
  • K Suzuki, T Ogura, T Yokose, et al.: Microsatellite instability in female non-small-cell lung cancer patients with familial clustering of malignancy. Br J Cancer. 77(6): 1003-8, 1998.
  • K Suzuki, K Takahashi, J Yoshida, et al.: Synchronous double primary lung carcinomas associated with multiple atypical adenomatous hyperplasia. Lung Cancer. 19(2): 131-9, 1998.
  • K Suzuki, J Yoshida, K Takahashi, et al.: Isolated mediastinal Hodgkin's disease mimicking thymoma: report of a case. Surg Today. 28(2): 213-6, 1998.
  • H Asamura, H Nakayama, H Kondo, et al.: Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg. 117(6): 1102-11, 1999.
  • H Asamura, M Ando, Y Matsuno, et al.: Histopathologic prognostic factors in resected adenocarcinomas: is nuclear DNA content prognostic? Chest. 115(4): 1018-24, 1999.
  • K Suzuki, K Nagai, J Yoshida, et al.: Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 67(4): 927-32, 1999.
  • K Suzuki, K Nagai, J Yoshida, et al.: Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg. 117(3): 593-8, 1999.
  • K Suzuki, K Nagai, J Yoshida, et al.: The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg. 118(1): 145-53, 1999.
  • K Suzuki, K Nagai, J Yoshida, et al.: Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer. 86(10): 1976-84, 1999.
  • K Suzuki, K Nagai, J Yoshida, et al.: Video-assisted thoracoscopic surgery for small indeterminate pulmonary nodules: indications for preoperative marking. Chest. 115(2): 563-8, 1999.
  • K Suzuki, T Yokose, T Yoshioka, et al.: Subclassification of Noguchi's type C adenocarcinoma of the lung. Jpn J Lung Cancer (Haigan, in Japanese). 39(1): 3-11, 1999.
  • K Suzuki, J Yoshida, M Nishimura, et al.: Postoperative mediastinal chyloma. Ann Thorac Surg. 68(5): 1857-8, 1999.
  • H Asamura, K Suzuki, H Kondo, et al.: Where is the boundary between N1 and N2 stations in lung cancer? Ann Thorac Surg. 70(6): 1839-45; discussion 1845-6, 2000.
  • H Asamura, H Kondo, R Tsuchiya: Management of the bronchial stump in pulmonary resections: a review of 533 consecutive recent bronchial closures. Eur J Cardiothorac Surg. 17(2): 106-10, 2000.
  • K Suzuki, T Yokose, J Yoshida, et al.: Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 69(3): 893-7, 2000.
  • K Suzuki, K Nagai, J Yoshida, et al.: Predictors of lymph node and intrapulmonary metastasis in clinical stage IA non-small cell lung carcinoma. Ann Thorac Surg. 72(2):352-6, 2001.
  • K Suzuki, H Asamura, M Kusumoto, et al.: "Early" peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg. 74(5):1635-9, 2002.
  • M Okada, W Nishio, T Sakamoto, et al.: Long-term survival and prognostic factors of 5-year survivorswith complete resection of non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 126(2): 558-562, 2003.
  • M Okada, T Sakamoto, W Nishio, et al.: Pleural lavage cytology in non-small cell lung cancer: Lessons from 1,000 consecutive resections. J Thorac Cardiovasc Surg. 126(6): 1911-5, 2003.
  • M Okada, T Sakamoto, W Nishio, et al.: Characteristics and prognosis of patients after resection of non-small cell lung carcinoma measuring 2 cm or less in greatest dimension. Cancer. 98(3): 535-541, 2003.
  • M Okada, W Nishio, T Sakamoto, et al.: Discrepancy of computed tomographic image between lung and mediastinal windows as a prognostic implication in small lung adenocarcinoma. Ann Thorac Surg. 76: 1828-1832, 2003.
  • H Asamura, K Suzuki, S Watanabe, et al.: A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. Ann Thorac Surg. 76(4): 1016-22, 2003.
  • Y Ichinose, Y Nakai, S Kudoh, et al.: Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 10(13): 4369-4373, 2004.
  • Y Ichinose, K Yoshimori, H Sakai, et al.: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 10(23): 7860-7864, 2004.
  • K Kubota, Y Ichinose, et al.: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 22(2): 254-261, 2004.
  • R Maruyama, Y Ichinose, et al.: Prognostic value of visceral pleural invasion in resected non-small cell lung cancer diagnosed by using a jet stream of saline solution. J Thorac Cardiovasc Surg. 127(6): 1587-1592, 2004.
  • T Okamoto, Y Ichinose, et al.: Clinical patterns and treatment outcome of elderly patients in clinical stage IB/II non-small cell lung cancer. J Surg Oncol. 87(3): 134-138, 2004.
  • T Yohena, Y Ichinose, et al.: Necessity of preoperative screening for brain metastasis in non-small cell lung cancer patients without lymph node metastasis. Ann Thorac Cardiovasc Surg. 10(6): 347-349, 2004.
  • I Yoshino, Y Ichinose, et al.: Multimodal treatment for resectable epithelial type malignant pleural mesothelioma. World J Surg Oncol. 2(1): 11-15, 2004.
  • Y Nakamura, C Endo, T Kondo, et al.: A New Technique for Endobronchial Ultrasonography and Comparison of Two Ultrasonic Probes: Chest. 126(1): 192-197, 2004.
  • S Yamanaka, M Sunamura, T Kondo, et al.: Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis: Laboratory Investigation. 84: 1339-1351, 2004.
  • M Okada, W Nishio, T Sakamoto, et al.: Correlation between computed tomographic findings, bronchioloalveolar carcinoma component and the biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg. 127: 857-861, 2004.
  • M Okada, W Nishio, T Sakamoto, et al.: Evolution of surgical outcomes for non-small cell lung cancer: Time trends in 1465 consecutive patients subjected to a complete resection. Ann Thorac Surg. 77: 1926-1930, 2004.
  • M Okada, W Nishio, T Sakamoto, et al.: Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: Analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 78: 216-221, 2004.
  • M Okada, W Nishio, T Sakamoto, et al.: Effect of histologic type and smoking status on the interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg. 78: 1004-1009, 2004.
  • M Okada, W Nishio, T Sakamoto: Sleeve segmentectomy for non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 128(3): 420-424, 2004.
  • Y Yatabe, T Koga, T Mitsudomi, et al.: CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 203: 645-52, 2004.
  • Y Yatabe, T Mitsudomi, T Takahashi: Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene. 23: 4041-9, 2004.
  • S Tomida, K Koshikawa, T Mitsudomi, et al.: Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 23: 5360-70, 2004.
  • J Takamizawa, H Konishi, T Mitsudomi, et al.: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64: 3753-6, 2004.
  • H Osada, Y Tatematsu, T Mitsudomi, et al.: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 112: 26-32, 2004.
  • T Koga, Y Horio, T Mitsudomi, et al.: Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data. J Mol Diagn. 6: 90-5, 2004.
  • T Kosaka, Y Yatabe, T Mitsudomi, et al.: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64: 8919-23, 2004.
  • H Endoh, S Tomida, T Mitsudomi, et al.: Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol. 22: 811-9, 2004.
  • K Shimizu, K Nagai, J Yoshida, et al.: Visceral pleural invasion classification in non-small cell lung cancer: A Proposal on the basis of outcome. J Thorac Cardiovasc Surg. 127: 1574-1578, 2004.
  • K Takamochi, J Yoshida, K Nagai, et al.: Prognosis and histologic features of small pulmonary adenocarcinoma based on Serum Carcinoembryonic Antigen level and computed tpmpgraphic findings. Eur.J.Cardio-thoracic Surg. 25: 877-883, 2004.
  • K Tsuta, G Ishii, K Nagai, et al.: Primary lung carcinoma with signet-ring cell carcinoma components clinicopathological analysis of 39 cases. Am J Surg Pathol. 17: 204-213, 2004.
  • Kim YH, G Ishii, K Nagai, et al.: Dominant papillary subtype is a significant predictior of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res. 10: 7311-7317, 2004.
  • H Nakamura, H Kato, et al.: An increase in the percentage of HLA-DR-positive peripheral leukocytes predicts a poor prognosis in patients with squamous cell carcinoma of the lung, Oncology Reports. 11,0-00, 2004.
  • F Taguchi, H Kato, et al.: hnRNP L enhances sensitivity of cells to KW-2189, Int. J. Cancer. 108(5): 679-685, 2004.
  • T Okunaka, H Kato, et al.: Photodynamic therapy for peripheral lung cancer, Lung Cancer. 43(1): 77-82, 2004.
  • H Nakamura, H Saji, H Kato, et al.: Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection, Lung Cancer. 44(1): 61-68, 2004.
  • T Shimamoto, T Hirano, H Kato, et al.: Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer, Potential prognostic implication. 12: 389-395, 2004.
  • N Ikeda, M Tsuboi, H Kato, et al.: A clinicopathological study of resected adenocarcinoma 2 cm or less in diameter, Ann. of Thoracic Surgery. 78(3): 1011-1016, 2004.
  • H Nakamura, Y Kato, H Kato: Outcome of surgery for small lung cancer-response to induction chemotherapy predicts survival, Thoracic Cardiovascular Surgery. 9(5): 378-382, 2004.
  • S Watanabe, H Asamura, K Suzuki, et al.: Recent results of postoperative mortality for surgical resections in lung cancer. Ann Thorac Surg. 78(3): 999-1002; discussion 1002-3, 2004.
  • K Suzuki, H Asamura, S Watanabe, et al.: Combined resection of superior vena cava for lung carcinoma: prognostic significance of patterns of superior vena cava invasion. Ann Thorac Surg. 78(4): 1184-9, 2004.
  • H Sakurai, A Maeshima, S Watanabe, et al.: Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 28: 198-206, 2004.
  • Y Oshiro, M Kusumoto, Y Matusno, et al.: CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. AJR. 182: 87-91, 2004.
  • H Asamura, K Suzuki, Y Matsuno, et al.: Thymoma needs a new staging system. Eur J Cardio-thorac Surg/Interactive Cardio-thorac Surg. 3: 163-7, 2004.
  • H Sakurai, T Hasegawa, S Watanabe, et al.: Inflammatory myofibroblastic tumor of the lung. Eur J Cardio-thorac Surg. 25: 155-9, 2004.
  • Jian SX, T Kamaya, H Asamura, et al.:HASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Modern Pathol. 17: 222-, 2004.
  • T Igarashi, Jian SX, T Kamaya, et al.: Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Modern Pathol 17: 1259-67, 2004.
  • N Sekiguchi, J Nishimoto, K Tanimoto, et al.: Primary mediastinal large B-cell lymphoma: a single-institution clinical study in Japan. Int J Hematol. 79: 465-71, 2004.
  • H Sakurai, H Asamura, S Watanabe, et al.: Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg. 78: 222-7, 2004.
  • H Sakurai, H Asamura, S Watanabe, et al.: Management of primary malignant germ cell tumor of the mediastinum. Jpn J Clin Oncol. 34: 386-92, 2004.
  • H Asamura.: Tumours of the thymus: Introduction. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the lung, pleura, thymus and heart. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds.: pp148-51, 2004.
  • 山中澄隆、佐藤雅美、桜田 晃、他:喫煙が予後に及ぼす影響の性差. 肺癌44(2):83―89, 2004.
  • R Maruyama, Y Ichinose, et al.: Triplet Chemotherapy with Cisplatin, Gemcitabine and Vinorelbine for Malignant Pleural Mesothelioma. Jpn J Clin Oncol., July, 2005.
  • T Okamoto, Y Ichinose, et al.: Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer. 47(1): 85-91, 2005.
  • T Okamoto, Y Ichinose, et al.: Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer. 41(9): 1286-1290, 2005.
  • F Shoji, Y Ichinose, et al.: Long-term survival after an aggressive surgical resection and chemotherapy for stage IV pulmonary giant cell carcinoma. World J Surg Oncol. 3(1): 32-35, 2005.
  • M Okada, W Nishio, T Sakamoto, et al.: Effect of tumor size on prognosis in non-small cell lung cancer:The role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 129(1): 87-93, 2005.
  • M Okada, T Sakamoto, T Yuki, et al.: Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors. J Thorac Cardiovasc Surg. 129(4): 825-830, 2005.
  • J Yoshida, K Nagai, T Yokose, et al.: Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience. J Thorac Cardiovasc Surg. 129: 991-996, 2005.
  • K Furukawa, T Miura, H Kato, et al.: Microwave coagulation Therapy in Canine Peripheral Lung Tissue, J. of Surgical Research. 123: 245-250, 2005.
  • Y Kato, T Hirano, H Kato, et al.: Frequent loss of E-cadherin and/or catenins in intrabroncial lesions during carcinogenesis of the bronchial epithelium, Lung Cancer. 48(3): 323-330, 2005.
  • K Fujii, T Nakano, H Kato, et al.: Clinical-scale high-throughput human plasma proteome analysis: Lung adenocarcinoma, Proteomics. 5: 1150-1159, 2005.
  • H Nakamura, K Fujita, H Kato, et al.: Expression pattern of the scaffold protein IQGAP1 in lung cancer, Oncology Report. 13(3): 427-431, 2005.
  • S Watanabe, H Asamura, K Suzuki, et al.: Problems in diagnosis and surgical management of clinical N1 non-small cell lung cancer. Ann Thorac Surg. 79(5): 1682-5, 2005.
  • H Asamura, T Kameya, Y Matsuno, et al.: Prognostic Spectrum of Pulmonary Neuroendocrine Neoplasms, J Clin Oncol, in press, 2005.
  • T Hirano, H Kato, J Maeda, et al.: Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker. Int J Cancer. 117: 460-468, 2005.
  • K Furukawa, H Kato, C Konaka, et al.: Locally recurrent central-type early stage lung cancer < 1.0 cm in diameter after complete remission by photodynamic therapy. Chest. 128: 3269-3275, 2005.
  • M Okada, T Sakamoto, Tsuyoshi, et al.: Hybrid surgical approach of video-assisted minithoracotomy for lung cancer. Chest. 128: 2696-2701, 2005.
  • H Harada, M Okada, T Sakamoto, et al.: Functional advantage following radical segmentectomy over lobectomy for lung cancer. Ann Thorac Surg. 80: 2041-2045, 2005.
  • Y Karube, T Mitsudomi, et al.: Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96: 111-115, 2005.
  • T Mitsudomi, et al.: Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients with Non-Small-Cell Lung Cancer With Postoperative Recurrence. J Clin Oncol. 23: 2513-2520, 2005.
  • S Toyooka, T Mitsudomi, et al.: EGFR mutation and response of lung cancer to gefitinib. N Engl J Med. 352: 2136; author reply 2136, 2005.
  • K Shimizu, J Yoshida, K Nagai, et al.: Visceral pleural Invasion is an Invasive and aggressive indicator of non-small cell lung Cancer. J Thorac Cardiovasc Surg. 130: 160-165, 2005.
  • Y Ichinose, et al.: UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer. 93:770-773, 2005.
  • M Taron, Y Ichinose, et al.: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 11:5878-5885, 2005.
  • R Rosell, Y Ichinose, et al.: Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer. 50:25-33, 2005.
  • Don Boming, M Sato, T Kondo, et al.: Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: They correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation. The Journal of Thoracic and Cardiovascular Surgery. 130(3): 733-739, 2005.
  • T Goya, H Asamura, H Kato, et al.: Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer. 50:227-234, 2005.
  • R Maruyama, Y Ichinose, et al.: Triplet chemotherapy for malignant pericardial mesothelioma: a case report. Jpn J Clin Oncol. 36:245-248, 2006.
  • M Okada, T Sakamoto, et al.: Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer. Ann Thorac Surg. 81: 1028-1032, 2006.
  • J Nagano, Y Ichinose, et al.: A Prospective Japanese Study of the Association between Personality and the Progression of Lung Cancer. Intern Med. 45:57-63, 2006.
  • J Ikeda, R Maruyama, Y Ichinose, et al.: Phase I Study of Amrubicin Hydrochloride and Cisplatin in Patients Previously Treated for Advanced Non-small Cell Lung Cancer. Jpn J Clin Oncol. 36:12-16, 2006.
  • T Seto, M Higashiyama, Y Ichinose, et al.: Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 53:91-96, 2006.
  • H Asamura, H Tada, et al.: Neuroendocrine neoplasms of the lung:a prognostic spectrum. J Clin Oncol. Jan 1 24(1): 70-76, 2006.
  • K Suzuki, Tsuchiya, H Asamura, et al.: Radiologic classification of small adenocarcinoma of the lung: radiologic- pathologic correlation and its prognostic impact. Ann Thorac Surg. 81: 413-419, 2006.
  • Y Tsushima, K Suzuki, S Watanabe, et al.: Multiple lung adenocarcinomas showoing ground-glass opacities on thoracic computed tomography. Ann Thorac Surg. 82:1508-10:2006.
  • H Asamura , T Goya, T Koshiishi, et al.: How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations. J Thorac Cardiovasc Surg . 132:316-19,2006.
  • H Asamura. Treatment of choice for stage I non-small cell lung cancer: surgery orradiotherapy? J Thorac Oncol . 1:766-77,2006.
  • Y Maniwa, M Yoshimura, VP Bermudez, et. al; His239Arg SNP of HRAD9 is associated with lung adenocarcinoma. Cancer.106 5: 1117-22,2006.
  • Y Yatabe, T Hida, Y Horio, et al.: A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 8: 335-41,2006.
  • S Toyooka, Y Yatabe, M Tokumo, et al.: Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer.118: 1588-90, 2006.
  • T Takeuchi, S Tomida, Y Yatabe, et al.: Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 24: 1679-88, 2006.
  • T Mitsudomi, T Kosaka, Y Yatabe. Biological and clinical implications of EGFR mutations in lung cancer. International journal of clinical oncology / Japan Society of Clinical Oncology.11: 190-8, 2006.
  • T Kosaka, Y Yatabe, H Endoh, et al.: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 12: 5764-9, 2006.
  • T Fukui, S Mori, K Yokoi, et al.: Significance of number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol. 1: 120-5, 2006.
  • H Endoh, Y Yatabe, T Kosaka, et al.: PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR mutated lung cancer patients. J Thorac Oncol. 1: 629-34, 2006.
  • K Nakagawa, H Tada, A Akashi, et al.: The Osaka Lung Cancer Study Group, Japan:Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. British Journal of Cancer. 95(7): 817-21.2006.
  • T Kosaka, Y Yatabe, H Endoh, et al.: Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clinical Cancer Research . 12(19): 5764-5769. 2006.
  • K Kawahara, T Nagano, T Inoue, et al.: AN EXTREMELY SOLID VARIANT OF ADENOID CYSTIC CARCINOMA ARISING IN THE LOWER TRACHEA.Archieves of Histopathologic Differential Diagnoses. 13 :10-14.2006.
  • R Maruyama, T Miyake, Y Ichinose, et al.: Establishment of a clinical pathway as an effective tool to reduce hospitalization and charges after video-assisted thoracoscopic pulmonary resection. Jpn J Thorac Cardiovasc Surg. 54:387-90, 2006.
  • T Seto, S Ushijima, Y Ichinose, et al.: Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer. 95:717-21, 2006.
  • T Yamanaka, T Okamoto, Y Ichinose, et al.: Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol. 11:167-75, 2006.
  • R Maruyama, R Suemitsu, Y Ichinose, et al.: Persistent and Aggressive Treatment for Thymic Carcinoma. Results of a Single-Institute Experience with 25 Patients. Oncology. 70:325-329, 2006.
  • H Saito, Y Takada, Y Ichinose, et al.: Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 24:5247-52, 2006.
  • T Okamoto, R Maruyama, Y Ichinose, et al.: Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 5:362-366, 2006.
  • T Uehara, T Yohena, Y Ichinose, et al.: A prospective trial of oral betamethason and oral lorazepam in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. Ryukyu Med J. 25:17-22, 2006.
  • Y Ichinose: A randomized phase III trial of adjuvant treatment for resected non-small cell lung cancer in Japan. Cancer Chemother Pharmacol. 58 Suppl 7:43-8, 2006.
  • J Okamoto, T Okamoto, Y Ichinose, et al.: The use of a water seal to manage air leaks after a pulmonary lobectomy: a retrospective study. Ann Thorac Cardiovasc Surg. 12:242-4, 2006.
  • T Hishida, K Nagai, J Yoshida, et al.: Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J. Thorac. Cardiovasc. Surg. 131: 838-842,2006
  • K Shimizu, J Yoshida, K Nagai.: Mediastinal lymph node metastases and visceral pleural invasion in nonsmall cell lung cancer patients. Ann Thorac Surg. 81: 1947,2006.
  • T Okano, T Kondo, K fujii, et al.: Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Clin Cancer Res.13(3): 799-805, 2007.
  • M Nomura, H Shigematsu, L Li, et al.: Polymorphisms, Mutations, and amplification of the EGFR Gene in Non-Small Cell Lung Cancer. PLoS Medicine. 4(4): 715-727, 2007.
  • R Maruyama, H Yokoyama, Y Ichinose, et al.: Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial. J Thorac Oncol. 2:65-8, 2007.
  • T Okamoto, R Maruyama, Y Ichinose, et al.: Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomy. Lung Cancer. 56:449-53, 2007.
  • K Nagai, Y Sohara, R Tsuchiya, et al.: Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases. J Thorac Oncol. 2: 282-286,2007.
  • 平野隆、加藤靖文、前田純一、他:気管支扁平上皮癌発癌過程における気管支壁内病巣の組織化学的検討. 気管支学 28(8): 601-605, 2007.
  • 羽隅 透、佐藤 伸之、近藤 丘他:原発性非小細胞肺癌完全切除例の遠隔転移巣に対する外科治療成績の検討.日本呼吸器外科学会雑誌.21(1): 11-15, 2007.
  • Y Ohno, M Yoshimura, et al,: Postoperative lung function in lung cancer patients: comparative analysis of predictive capability of MRI, CT, and SPECT. Am J Roentgenol. 189(2):400-8,2007.
  • Y Ohno, M Yoshimura, et al,: Coregistered ventilation and perfusion SPECT using krypton-81m and Tc-99m-labeled macroaggregated albumin with multislice CT utility for prediction of postoperative lung function in non-small cell lung cancer patients. Acad Radiol. 14(7):830-8,2007.
  • T Yuki, M Yoshimura, et al,: Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg. 134(2):399-404,2007.
  • T Mimura, M Yoshimura, et al,: Novel marker D2-40, combined with calretinin, CEA, and TTF-1:an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 109(5):933-8,2007.
  • Y Ohno, M Yoshimura, et al,: Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging. 26(3):498-509,2007.
  • Y Ohno, M Yoshimura, et al,: STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: Quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. J Magn Reson Imaging. 26(4):1071-80,2007.
  • M Takata, M Yoshimura, et al,: Double-layered collagen gel hemisphere for cell invasion assay: Successful visualization and quantification of cell invasion activity. Cell commun adhes. 14(4):157-67,2007.
  • K Aokage, G Ishii, K Nagai, et al,: Intrapulmonary metastasis in resected pathologic StageⅢB non-small cell lung cancer: Possible contribution of aerogenous metastasis to the favorable outcone. J Thorac Cardiovasc Surg. 134: 386-391. 2007.
  • H Nakamura, H Kato et al.: Epidermal Growth Factor Receptor Gene Mutations in Early Pulmonary Adenocarcinomas. Ann Thorac Cardiovasc Surg. 13(2): 87-91, 2007.
  • G Marko-Varga G, H Kato et al,: Personalized Medicine and Proteomics: Lessons from Non-Small Cell Lung Cancer. Journal of Proteome Research. 6(8): 2925-2935, 2007.
  • J Usuda, H Kato et al,: Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy. Lung Cancer. 58: 317-323, 2007.
  • J Maeda, H Kato et al,: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualization of postoperative therapy. British Journal of Cancer. 98: 596-603, 2007.
  • T Hishida, J Yoshida, K Nagai, et al,: Problems in the current diagnostic standards of Clinical N1 non-small cell lung cancer. Thorax. 63: 526-531. 2008.
  • T Mizuno, G Ishii, K Nagai, et al,: Identification of a low risk subgroup of stage ⅠB lung adenocarcinoma patients. Lung Cancer. 2008.

4. 総説・解説

  • HI Pass, H Kato, DA Cortese, et al.: LUNG CANCER (The Use of Light for the Early Detection and Treatment of Lung Cancer). Lippincott William & Wilkins. 425-437, 2000.
  • RJ Korst, R Tsuchiya, et al.: 11,Treatment of non-small cell lung cancer; 11.1, Treatment of NSCLC: Radiotherpy. Textbook of Lung Cancer, 2000.
  • 多田弘人:非小細胞肺癌の術前治療. 肺癌の臨床. 4(1):43-47, 2001.
  • 光冨徹哉:分子生物学的マーカーの集学的治療における意義. 肺癌の臨床. 4:19-25, 2001.
  • S Yano, M Kusumoto, H Asamura, et al.: A case of Mycobacterium avium Complex Infection Showing Solitary Pulmonary ass. Radiat Med. 20(3): 151-154, 2002.
  • T Mitsudomi: Molecular lesions as targets for diagnosis and therapy of lung cancer. Jpn J Cacner Chemother. 29 (SI): 112-116, 2002.
  • 光冨徹哉:肺癌の予後因子 分子マーカーを中心に. Medical Practice. 19:14-20, 2002.
  • 阿知和宏行、光冨徹哉:抗癌剤感受性の予測、治療学. 36:21-24, 2002.
  • 光冨徹哉:肺がんの予後因子 分子マーカーを中心に. 呼吸器科. 2:201-207, 2002.
  • 多田弘人:標準的治療と今後の有望な治療法-これが今の、5年後のEBMだ!-限局型小細胞肺癌. Medical Practice. 19:107-110, 2002.
  • 多田弘人:肺癌の再発診療に関する最新のデータ. 臨床外科. 増刊号. 57:69-72, 2002.
  • 光冨徹哉:肺がんの分子病態、がん分子標的治療. 1:72-77, 2003.
  • 奥仲哲弥、加藤治文: Sentinel node navigation surgeryの現状と展開 5.各臓器におけるSNNSの現状とその成績 c.肺癌. 日本外科学会雑誌104(11): 778-780, 2003.
  • H Kato, H Nakamura, M Tsuboi, et al.: Treatment of Peripheral Early Stage Lung Cancer, Ann. of Thoracic and Cardiovascular Surgery. 10(1): 1-3, 2004.
  • H Kato, M Harada, S Ichinose, et al.: Photodynamic therapy (PDT) of lung cancer: experience of the Tokyo Medical University, Photodiagnosis and Photodynamic Therapy. 1(1): 49-55, 2004.
  • H Kato, J Usuda, T Okunaka, et al.: The history of the study of photodynamic therapy (PDT) and photodynamic diagnosis (PDD) in the department of Surgery, Tokyo Medical University, Photodiagnosis and Photodynamic Therapy. 1(1): 107-110, 2004.
  • H Kato, M Tsuboi, Y Kato, et al.: Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer, Int. J Clinical Oncology. 10: 157-164, 2005.
  • 遠藤秀紀, 光冨徹哉.:肺癌診断の最前線 遺伝子診断. 呼吸器科. 6: 251-7, 2004.
  • 光冨徹哉:肺がんにおけるEGFR遺伝子発見の衝撃. 治療学. 38: 84, 2004.
  • 中村治彦、加藤治文:Oncogenic emergencyとその対応 3.肺癌、日本外科学会雑誌105(4):271-273, 2004.
  • 加藤治文:ガイドラインからみた肺癌外科の構築 1.特集によせて(JCOGの試み)、日本外科学会雑誌105(7):387, 2004.
  • 池田徳彦、坪井正博、加藤治文:ガイドラインからみた肺癌外科の構築 4.リンパ節転移を伴う肺癌の治療ガイドライン、日本外科学会雑誌105(7): 404-407, 2004.
  • 多田弘人:気道狭窄に対する治療. 気管支学. 26(7): 667-670, 2004.
  • 坪井正博、加藤治文:肺癌の拡大手術と縮小手術-その評価と展望 2.非小細胞肺癌拡大手術の適応、日本外科学会雑誌. 106(6): 367-374, 2005.
  • H Kato, M Harada, Pass HI, et al.: The use of photodynamic therapy for lung cancer. Philadelphia: Lippincott Williams & Wilkins; Lung Cancer; Principles and Practice. 3rd ed. 842-849, 2005.
  • S Tomida, T Mitsudomi, et al.: Throwing new light on lung cancer pathogenesis: Updates on three recent topics. Cancer Sci,.96: 63-68, 2005.
  • T Ohira, H Kato, et al.: Early-stage lung cancer: diagnosis and treatment, International Journal of Clinical Oncology. 11(1):9-12, 2006.
  • 坪井正博, 加藤治文.: 非小細胞肺癌の術後補助化学療法の現状と展望. 篠原出版新社・MOOK2004-2005「肺癌の臨床」. 223-230, 2005年
  • 坪井正博, 加藤治文, 奥仲哲弥.: 非小細胞肺がんの術後adjuvant療法. 中外医学社・癌化学療法のupdate. 408-414, 2005年
  • 大平達夫, 加藤治文.: 非小細胞肺癌 IA期に対する標準的手術は?. 中外医学社・EBM呼吸器疾患の治療2006-2007. 413-415, 2005.
  • 加藤治文.: 臨床医学の展望:呼吸器外科学. 日本医事新報. 4216、37-46、2005.
  • 臼田実男, 加藤治文.: 癌治療における光線力学的治療の現況. Biotherapy. 19: 311-316, 2005.
  • 古川欣也, 石田順造, 加藤治文, 他.: 中枢気道悪性病変に対する気管支鏡下治療. 外科治療. 93: 456-464, 2005.
  • 大平達夫, 坪井正博, 加藤治文.: 【癌術後フォローアップ計画】 肺癌. コンセンサス癌治療. 4: 36-38, 2005.
  • 光冨徹哉: 検診とゲノム診断. 肺癌. 45: 157-165, 2005.
  • 光冨徹哉、他: 分子マーカーEGFR遺伝子変異発見の衝撃. MOOK肺癌の臨床 247-257, 2005.
  • 光冨徹哉、他: 肺癌におけるEGFR遺伝子の突然変異と分子標的治療発見から一年をへて. Cancer Frontier. 7: 89-96, 2005.
  • 光冨徹哉: 肺癌におけるEGFR変異の集積. 分子呼吸器病. 9: 128-132, 2005.
  • 高坂貴行、光冨徹哉、他:: 肺癌のトランスレーショナルリサーチ―EGFR 遺伝子変異―.癌と化学療法. 癌と化学療法社. 32巻6号: 750-758, 2005.
  • 光冨徹哉: EGFR遺伝子変異とEGFRチロシンキナーゼ阻害剤. Focus on Oncology. 4: 17-19, 2005.
  • 光冨徹哉: EGFR遺伝子変異-ゲフィチニブとの関連を探る. 分子呼吸器病. 9: 501-503, 2005.
  • 遠藤秀紀、光冨徹哉、他: 遺伝子診断の新しい試みEGFR遺伝子変異を中心に. Lung Cancer Today. メディカルレビュー社. 2005夏号 5巻3号: 15-18, 2005.
  • 光冨徹哉: EGF受容体遺伝子変異とゲフィチニブの感受性. がん分子標的治療. 3: 304-311, 2005.
  • 雪上晴弘、光冨徹哉: 肺癌に対する低侵襲外科手術の現状と進歩. Pharma Medica. 23: 23-27, 2005.
  • 森正一、光冨徹哉: 肺癌の手術療法. コンセンサス癌治療. へるす出版. 4巻4号: 186-189, 2005.
  • 岡田守人: 再ミニ開胸(VATS)による区域切除. 肺癌. 45: 261-266, 2005.
  • 岡田守人: 呼吸器外科手術の基礎知識―肺癌に対する拡大手術― 呼吸器ケア. 3: 77-81, 2005.
  • 岡田守人: 肺癌の治療2005-2007 胸膜中皮腫の外科治療 コンセンサス癌治療. 4: 228-229, 2005.
  • 岡田守人: 増え続ける肺癌/治療成績を向上させるために 末梢小型肺癌に対するアプローチ. 外科治療. 93: 421-426, 2005.
  • 岡田守人, 坪田紀明: 肺癌拡大区域切除の成績と適応. 日本外科学会雑誌. 106: 395-399, 2005.
  • 一瀬幸人: UFTを用いた術後補助化学療法. 肺癌. 45:801-803, 2005.
  • 丸山理一郎, 一瀬幸人: 治療 非小細胞肺癌 隣接臓器合併切除の適応と治療成績改善の工夫. Mook肺癌の臨床.207-214, 2005.
  • 綿屋洋, 一瀬幸人: 目でみる症例 粘液産生性気管支肺胞上皮癌. 内科. 96:929-933, 2005.
  • 綿屋洋, 一瀬幸人: 新規抗がん剤 S-1. 呼吸器科. 7:496-501, 2005.
  • 岡本龍郎, 一瀬幸人: 【肺癌診断・治療の最新情報】 非小細胞肺癌の術後化学療法. 癌と化学療法. 32:765-769, 2005.
  • 岡本龍郎, 一瀬幸人: 【早期非小細胞肺がんに対する最新治療動向】 術前導入療法. 呼吸器科. 7:107-111, 2005.
  • 一瀬幸人: 治療の進歩 非小細胞肺癌術後化学療法の再評価. Annual Review呼吸器. 2005:238-243, 2005.
  • 多田弘人: 特集臨床腫瘍学の現状と展望 V.がん薬物療法の実際 1.肺癌 3)術後のアジュバント療法. Progress in Medicine. 25(.8): .61(2043)-65(2047), 2005.
  • 多田弘人: 6.III期非小細胞肺癌の治療 (2)外科の立場から、コンセンサス癌治療. 4(4): 200-203, 2005.
  • 多田弘人: 非小細胞肺癌に対する術前治療、MOOK肺癌の臨床2004-2005 疫学 発見 診断 治療. 篠原出版新社. 215-221, 2005.
  • 高坂貴行、光冨徹哉、他: EGFR遺伝子変異とゲフィチニブ感受性. 科学評論社. 呼吸器科. 9巻2号: 151-158, 2006.
  • 岡田守人: 中皮腫トピックス 外科療法. 日本胸部臨床. 65: 646-650, 2006.
  • 岡田守人: 小型肺がんに対する区域切除. Annual Review 呼吸器 2006. 238-243, 2006.
  • 丸山理一郎, 岡本龍郎, 一瀬幸人: 【使用する立場からみた「癌診療ガイドライン」のポイント】 肺癌診療ガイドライン. 外科治療. 94:170-178, 2006.
  • 岡本龍郎, 一瀬幸人: 【非小細胞肺がんに対する化学療法の最新動向】 非小細胞肺がんの術前治療. 呼吸器科. 9:124-127, 2006.
  • 瀬戸貴司、一瀬幸人: 癌性胸膜炎の診断と治療(悪性胸膜中皮腫を含む). 臨床外科. 61:741-746, 2006.
  • 多田弘人: 小細胞肺癌の外科、MOOK肺癌の臨床2005-2006. 篠原出版新社. 187-192, 2006.
  • H Kato, J Usuda, T Okunaka, et al.: Basic and Clinical Research on Photodynamic Therapy at Tokyo Medical University Hospital. Lasers in Surgery and Medicine 38: 371-375, 2006.
  • T Mitsudomi, T Kosaka, Y Yatabe. : Smoking history and response to EGFR TKIs. Signal, 6: 4-9, 2006.
  • 坪井正博、加藤治文:Adjuvant and Neoadjuvant Chemotherapy 肺癌. Mebio Oncology 3(4): 13-19, 2006.
  • 高坂貴行, 遠藤秀紀, 恭 谷,他.: EGFR遺伝子変異とゲフィチニブ感受性. 呼吸器科. 9: 151-8, 2006.
  • 関戸好孝, 光冨徹哉. : 肺がんの遺伝子診断. Mook 肺癌の臨床 2005-2006: 177-83, 2006.
  • 谷田部恭, 光冨徹哉. : 肺癌におけるEGFR遺伝子変異. Biotherapy, 20: 223-30, 2006.
  • 清水淳市, 光冨徹哉. :EGFR-TKI, HER-1阻害薬. CancerFrontier 分子標的治療: 8-17, 2006.
  • 光冨徹哉. :肺癌の分子標的治療 イレッサの作用機序とEGFR遺伝子変異. 愛知医報. 1778: 4-9, 2006.
  • 光冨徹哉. :肺がんにおけるEGFR遺伝子変異と分子標的治療. 血液・腫瘍科. 52: 453-9, 2006.
  • 多田弘人: 早期非小細胞肺癌の術後補助化学療法.最新医学.第61巻11号: 35-39.2006.
  • 一瀬幸人. : 非小細胞肺がん-Early stage-. In: Key Trial [がん]: 先端医学社; 2006.
  • 一瀬幸人. : VIII.治療各論 [A]非小細胞肺癌の治療の実際 ②切除可能症例における集学的治療 2.術前治療 治療法の選択にあたって. 工藤翔二(監修), 江口研二, 横井香平, 弦間昭彦(編集), 呼吸器common diseaseの診療 肺癌のすべて. 東京: 分光堂; 2006. p. 306-307.
  • 岡本龍郎, 一瀬幸人: 特集/Adjuvant Chemotherapyno動向.肺癌におけるAdjuvant chemotherapyの動向. Focus on Oncology. 5:4-7, 2006.
  • 綿屋洋, 一瀬幸人: 【S-1の基礎と臨床】 進行非小細胞肺がんに対するS-1+Cisplatinの併用療法. 癌と化学療法. 33:194-196, 2006.
  • 岡本龍郎, 一瀬幸人: 肺癌の術後化学療法の現状と問題. 癌と化学療法. 33:1985-1990, 2006.
  • 岡本龍郎, 瀬戸貴司, 一瀬幸人: 【外来化学療法の適正管理】 標準外来化学療法 肺がん. 医薬ジャーナル. 42:2138-2142, 2006.
  • 一瀬幸人: 外科学温故知新 臨床試験. 臨床外科. 61:1087-1092, 2006.
  • 加藤治文、田中浩一、木下孔明:非小細胞肺癌に対するAdjuvant Chemotherapy. Focus on Oncology 6: 5-7, 2007.
  • 佐治久、坪井正博、高橋充、他:悪性胸膜中皮腫の治療経験と今後の課題-外科関連治療を中心に-. 癌の臨床 52(11): 679-683, 2007.
  • 多田弘人:Ⅷ-A.非小細胞肺癌の治療の実際 ③切除可能症例における集学的治療 2.術前治療. 肺癌のすべて.文光堂:302-305.2007.
  • 山崎宏司, 一瀬幸人: 肺がん患者への術後補助化学療法をめぐって. 臨床腫瘍プラクティス. 3:219-224, 2007.
  • K Nagai, et al,: Postoperative mortality in lung cancer patients. Ann Thorac cardiovasc Surg 13:373-375,2007.
  • 多田弘人:肺癌の再発診療に関する最新のデータ. 臨床外科 62(11):97-100,2007.
  • 多田弘人: 非小細胞肺癌-補助療法の考え方は?. EBM呼吸器疾患の治療.中外医学社:323-326,2007.
  • 中嶋隆、多田弘人: 術前導入療法とは、どんな治療ですか?. ナーシングケアQ&A(徹底ガイド肺がんケアQ&A)19:123-125,2008.
  • 多田弘人: 縦隔鏡検査. MOOK肺癌の臨床2008~2009. 篠原出版社: 137-140,2008.

b. 主な学会発表

1. 委員会承認の治療研究

JCOG8601
M Ohta, R Tsuchiya, M Shimoyama, et al.: Adjuvant Chemotherapy for Completely Resected Stage III Non-small-cell Lung Cancer. 6th World Congress on Lung Cancer. Nov 1991.
JCOG9101
R Tsuchiya, Y Watanabe, T Yasumitsu, et al.: Surgery & adjuvant chemotherapy (CT) for small cell lung cancer (SCLC). 8th World Congress on Lung Cancer. Aug 1997.
中川勝裕、小池輝明、永井完治、他:肺小細胞癌(病理病期I, II, IIIA)に対する術後化学療法、第II相試験. 第41回日本肺癌学会総会. 2000年11月.
K Suzuki, R Tsuchiya, Y Ichinose, et al.: Phase II Trial of Postoperative Adjuvant Cisplatin and Etoposide in Patients with Completely Resected Stage I - IIIa Small Cell Lung Cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). Proceedings of ASCO. 19:492a, 2000.
JCOG9304
小池輝明、多田弘人、一瀬幸人、他:N2肺非小細胞がんに対する術後化学療法の比較試験. 第41回日本肺癌学会総会. 2000年11月.
Y Ichinose, H Tada, T Koike, et al.: A randomized phase III trial of postoperative adjuvant chemotherapy in patients with completely resected stage IIIa-n2 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG 9304) trial. 37th Annual Meeting of the American Society of Clinical Oncology. May 2001.
光冨徹哉、谷田部恭、多田弘人、他:多施設共同臨床試験における分子マーカーの意義(JCOG9304付随研究). 第42回日本肺癌学会総会. 2001年11月.
T Mitsudomi, Y Yatabe, H Tada, et al.: Lack of predictive value of p53, p27, Bcl2, HER2/neu, EGFR alterations for efficacy of postoperative adjuvant chemotherapy consisting of cisplatin plus vindesine in patients with non-small cell lung cancer with mediastinal node invovement (JCOG9304A). In: Annual Meeting of the American Society of Clinical Oncology. Chicago, May 2003.
JCOG9805
H Kunitoh, N Saijo, H Tada, et al.: A Pilot Trial of Preoperative MVP-Combined Chemoradiotherapy: Mitomycin C (mmc), Vindesine (VDS), and Cisplatin (CDDP), Concurrentry Given with Thoracic Radiotherapy (TRT) in N2 Non-Small Cell Lung Cancer (NSCLC). 36th Annual Meeting of the American Society of Clinical Oncology. May 2000.
JCOG9806
H Kunitoh, H Kato, et al.: A phase II trial of pre-operative chemoradiotherapy followed by surgical resection in pancoast tumors. Initial report of Japan Clinical Oncology Group Trial (JCOG 9806). Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology. May 2003.
M Tsuboi, H Kato, et al.: A Phase II Trial of pre-operative chemoradiotherapy followed by surgery in Pancoast tumors: initial report of Japan Clinical Oncology Group trial (JCOG9806). 10th World Conference on Lung Cancer, Aug 2003.
Y Ichinose, H Kunitoh, H Kato, et al.: A phase II trial of chemoradiotherapy followed by surgery in Pancoast tumors: initial report of the Japan Clinical Oncology Group trial (JCOG 9806). ECCO12. Sep 2003.
K Suzuki, H Kunitoh, Y Ichinose, et al.: Phase II trial of preoperative chemoradiotherapy for superior sulcus tumor. JCOG 9806. 11th World Conference on Lung Cancer, 2005.
JCOG0201
K. Suzuki, T. Koike, T. Shibata, et al.: Evaluation of radiologic diagnosis in peripheral clinical IA lung cancers--A prospective study for radiological diagnosis of peripheral early lung cancer (JCOG 0201). 42nd Annual Meeting of the American Society of Clinical Oncology.Jun 2006.
小池輝明、鈴木健司、淺村尚生、他:胸部薄切CT所見に基づく肺野型早期肺癌の診断とその妥当性に関する前向き研究(JCOG0201). 第47回日本肺癌学会総会. 2006年12月.
COG0204
H Tada, H Katoh, H Kunitoh, et al.: A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II nonsmall cell lung cancer (NSCLC): Initial report of Japan Clinical Oncology Group trial (JCOG 0204). 11th World Conference on Lung Cancer. Jul 2005.

2. グループ代表者管理の治療研究

  • M Sagawa, Y Saito, S Fujimura, et al.: A case-control study for evaluating the early detection program of lung cancer in Miyagi Prefecture, Japan. AACR (Apr 1999, Philadelphia, PA, U.S.A.).
  • 佐川元保、小池輝明、佐藤雅美、他:胸部X線無所見肺扁平上皮癌に対する区域切除術-JCOG肺がん外科グループ. 第40回日本呼吸器学会総会. 2000年3月.
  • 一瀬幸人、加藤治文、小池輝明、他:完全切除IIIAN2非小細胞肺癌例の予後-JCOG肺がん外科グループにおける406例の解析結果-. 第53回日本胸部外科学会総会. 2000年10月.
  • M Tsuboi, Y Ichinose, H Kato, et al.: Overall Survival and Local Recurrence after complete surgical resection with standard lymph node dessecion in cases of pN2 Non-Small Cell Lung Cancer. The Second International Workshop on Surgical Exploration of the Mediastinum and Systemic Nodal Dissection. Nov 2000.
  • 一瀬幸人、加藤治文、小池輝明、他:完全切除IIIAN2非小細胞肺癌における原発巣の部位と転移リンパ節station数の重要性. 第54回日本胸部外科学会総会. 2001年10月.
  • M Tsuboi, H Kato, N Saijo: Japanese trial in resectable lung cancer. Fourth Congress on Lung Cancer. Nov 2001.
  • H Asamura, T Kameya, Y Matsuno, et al.: Prognostic Spectrum of Pulmonary Neuroendocrine Neoplasms, J Clin Oncol, in press, 2005.
  • 坪井正博, 加藤治文.: 肺がん外科におけるRCTの問題点. 第105回日本外科学会定期学術集会シンポジウム.・2006年5月.
  • M Tsuboi, H Kato, Y Ichinose, et al.: The influence of tumor size, histological differentiation and smoking history in patients with completely resected stage I adenocarcinoma of the lung. 42nd ASCO Annual Meeting. Jun 2006.

3. 附随研究等

  • Y Ichinose: Symposium: Japanese trials of neoadjuvant treatment for N2 non-small cell lung cancer. 9th World Conference on Lung Cancer. Sep 2000.
  • M Saito, C Konaka, H Kato, et al.: Lymph node status of small lung cancers: 2.0 cm or less in size. 9th World Conference on Lung Cancer. Sep 2000.
  • M Saito, C Konaka, H Kato, et al.: Prognostic factors and nodular status of radical systemic mediastinal lymphadenectomy in patients of pN2 non-small cell lung cancer. 9th World Conference on Lung Cancer. Sep 2000.
  • H Tada: Neoadjuvant chemo-radiotherapy for LD small cell lung cancer: A pilot study. 25th Congress of the European Society for Medical Oncology. Oct 2000.
  • K Furukawa, N Ikeda, T Miura, et al.: Early Detection of Central Type Lung Carcinoma using Autofluorescence Bronchoscopy. 14th International Congress of Cytology Amsterdam. Netherlands. May 2001.
  • M Tsuboi, H Kato, C Konaka, et al.; NK421 Lung Cancer Study Group: A randomized phase III Study comparing Ubenimex(Bestatin) versus placebo as postoperative adjvant treatment in patients with stage I squamous cell lung cancer. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology. May 2001.
  • N Ikeda, T Ohira, T Hirano, et al.: The possibility of clinical application of Malignancy Associated Changes for early detection of lung cancer. Third International Conference on Prevention and Early Detection of Lung Cancer. Aug 2001.
  • H Tada, T Yasumitsu, K Iuchi, et al.: Randomized study of adjuvant chemotherapy for completely resected non-small cell lung cancer: lack of prognostic significance in DNA ploidy pattern at adjuvant setting. 38th Annual Meeting of the American Society of Clinical Oncology. May 2002.
  • 林 明男、多田弘人、山本良二、他:IIIA期N2非小細胞肺癌に対する、術前化学療法+縦隔のみの同時併用放射線療法の施行例の検討. 第76回日本肺癌学会関西支部会. 2002年8月.
  • 池田直樹、多田弘人、松田 暉、他:硫酸転移酵素GP3ST遺伝子導入によるスルホルイス抗原とシアリルルイス抗原の変動. 第61回日本癌学会総会. 2002年10月.
  • 多田弘人、山本良二、東条 尚、他:cN2 非小細胞肺癌に対する術前化学療法と放射線併用療法の違いについて. 第55回 日本胸部外科学会総会. 2002年10月.
  • 多田弘人、根来俊一、田中正博、他:小細胞がんに対する最近の治療戦略 限局型小細胞肺癌に対するtrimodality. 第40回日本癌治療学会総会. 2002年10月.
  • T Tojo, H Tada, R Yamamoto, et al.: CTfindings of Large Cell Neuroendocrine Carcinoma. CHEST. Nov 2002.
  • 太田三徳、大倉英司、船越康信、他:T4肺癌の治療ー特に大血管浸潤肺癌について. 第43回日本肺癌学会総会. 2002年11月.
  • 杦浦孝宗、武田晃司、尾崎智博、他:CT画像上Ground Glass Attenuation(GGA)を呈する末梢型早期肺癌の検討. 第43回日本肺癌学会総会. 2002年11月.
  • 池田直樹、本家孝一、多田弘人、他:硫酸転移酵素GP3ST遺伝子導入によるスルホルイス抗原とシアリルルイス抗原の変動. 第43回日本肺癌学会総会. 2002年11月.
  • 池田直樹、多田弘人、巽光朗、他:縦隔腫瘍診断におけるFDG-PETの有用性. 第43回日本肺癌学会総会. 2002年11月.
  • 尾崎智博、瀧藤伸英、片山博文、他:確定診断に難渋した空洞形成を伴った原発性腺癌の1例. 第77回日本肺癌学会関西支部会. 2003年2月.
  • 池田直樹、山本良二、東条尚、他:IV期肺癌切除後の長期生存例. 第77回日本肺癌学会関西支部会. 2003年2月.
  • 杦浦孝宗、瀧藤伸英、片山博文、他:ゲフィチニブ市販後投薬例の臨床的検討. 第77回日本肺癌学会関西支部会. 2003年2月.
  • 多田弘人、山本良二、東条 尚、他:肺癌の切除成績の向上はbiasによるものである. 第20回日本呼吸器外科学会総会. 2003年5月.
  • 林 明男、多田弘人、山本良二、他:顆粒球コロニー刺激因子(G-CSF)産生肺癌の1切除例. 第20回日本呼吸器外科学会総会. 2003年5月.
  • Y Ichinose, T Seto, H Yamamoto, et al.: Intrapleural hypotonic cisplatin treatment (HPT) for malignant pleural effusion in 80 patients with non-small cell lung cancer (NSCLC). 39th Annual Meeting of the American Society of Clinical Oncology. May 2003.
  • M Tsuboi, H Kato, et al.: A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological Stage I (T1N0M0, T2N0M0) adenocarcinoma of the Lung. Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology. May 2003.
  • 池田直樹、本家孝一、多田弘人、他:硫酸転移酵素GP3ST遺伝子導入によるスルホルイス抗原とシアリルルイス抗原の変動. 第103回日本外科学会定期学術集会. 2003年6月.
  • 長谷川 喜一、瀧藤伸英、片山博文、他:ゲフィチニブ市販後投与例の臨床的検討. 第78回日本肺癌学会関西支部会. 2003年7月.
  • Y Ichinose, Y Takada, K Matsui, et al.: Phase II trial of irinotecan plus cisplatin after cisplatin plus etoposide and concurrent thoracic radiotherapy (TRT) in small cell lung cancer (SCLC) patients with limited disease: West Japan Thoracic Oncology Group 9902. 10th World Conference on Lung Cancer. Aug 2003.
  • Y Ichinose, Y Fukuyama, H Asoh, et al.: Induction Chemoradiotherapy and Surgical Resection for Selected Stage IIIB Non-Small Cell Lung Cancer. 10th World Conference on Lung Cancer. Aug 2003.
  • H Tada, T Yasumitsu, K Iuchi, et al.: Randomized control study of adjuvant chemotherapy with UFT alone or plus cisplatin and vindesine in patients with completely resected Non-small cell lung cancer. 10th World Conference on Lung Cancer. Aug 2003.
  • M Tsuboi, K Furukawa, A Hayashi, et al.: The feasibility study for the implantation of spiral Z stents in malignant tracheobronchial stenoses; a prospective multicenter trial. 10th World Conference on Lung Cancer. Aug 2003.
  • K Suzuki, K Nagai, et al.: Microsatellite Instability in Female Non-Small Cell Lung Cancer Patients with Familial Clustering of Malignancy. 8th World Conference on Lung Cancer, 1997.
  • K Suzuki, K Nagai, et al.: Clinical predictors of pathological N2 disease in CT negative NSCLC. Proceedings of ASCO (34th ASCO), 1998.
  • K Suzuki, K Nagai, et al.: Clinical predictors of extrathoracic metastases in clinical T1-2 N0 non-small cell lung cancer patients: Indications for systemic preoperative metastases investigation. Proceedings of ASCO (35th ASCO). 1999.
  • K Suzuki, H Asamura, H Kondo, et al.: Clinical predictors of minimally invasive peripheral adenocarcinoma of the lung: Possible indications for limited surgical resection. Lung Cancer 29(S1): 142. 9th World Conference on Lung Cancer, 2000.
  • K Suzuki, K Nagai, et al.: Clinical predictors of postoperative brain metastasis in lung cancer. Proceedings of ASCO (37th ASCO), 2001.
  • M Okada, K Uchino, T Sakamoto, et al.: Role of the tumor-suppressor TSLC1 (tumor suppressor in lung cancer 1) gene as a prognostic factor in lung adenocarcinoma . CHEST2003; Annual International Scientific Assembly of the American College of Chest Physician. Oct 2003.
  • M Okada, K Uchino, T Sakamoto, et al.: Discrepancy of computed tomography images between lung and mediastinal windows as a prognostic significance in small-sized lung adenocarcinoma . CHEST2003; Annual International Scientific Assembly of the American College of Chest Physician. Oct 2003.
  • K Suzuki.: Combined modality for N2 NSCLC. Risk for right side pneumonectomy. 9th Central European Lung Cancer Conference, 2003.
  • 岡田守人、西尾 渉、阪本俊彦、他: 根治性とQuality of lifeの維持を追求した肺癌手術の進化 -原発性肺癌手術1788例の検討-. 第20回日本呼吸器外科学会総会. 2003年5月.
  • 岡田守人、西尾 渉、阪本俊彦、他: Long-term survival and prognostic factors of 5-year survivors with complete resection of non-small cell lung carcinoma. 第103回日本外科学会総会. 2003年6月.
  • 岡田守人、西尾 渉、阪本俊彦、他: 積極的縮小手術適応基準の模索;術前CT画像のGGOとTDRは切除標本のBACを如何に反映するか. 第56回日本胸部外科学会総会. 2003年11月.
  • 岡田守人、西尾 渉、阪本俊彦、他:局所進行肺癌に対する集学的治療における手術の安全性;Induction therapyは術後合併症のリスクを増大させるか. 第56回日本胸部外科学会総会. 2003年11月.
  • Y Ichinose, K Itoh, F Imamura, et al.: Triplet combination chemotherapy of cisplatin, gemcitabine and vinorelbine with lower doses maintains a sufficient effect while avoiding toxicity in non-small cell lung cancer patients. 40th Annual Meeting of the American Society of Clinical Oncology. Jun 2004.
  • Y Ichinose.: Special recture: A step forward to the treatment of lung cancer. The 36th Annual Congress of the Korean Society for Thoracic and Cardiovascular Surgery. Nov 2004.
  • Y Ichinose.: New antitumor agents under development in the US, Europe and Japan: Chemotherapy trials using DPD-inhibitory fluoropyrimidine (S-1) for advanced non-small cell lung cancer patients in Japan. The 9th International Symposium on Cancer Chemotherapy. Dec 2004.
  • Y Ichinose.: Special Lecture: Current status and perspective of postoperative adjuvant chemotherapy in completely resected non-small cell lung cancer patients. The 2004 Annual Meeting of Taiwan Society of Pulmonary and Critical Care Medicine. Dec 2004.
  • K Suzuki, H Asamura, S Watanabe, et al.: Combined resection of superior vena cava for lung carcinoma: prognostic significance of patterns of superior vena cava invasion. Annual meeting of Society of Thoracic Surgeons , 2004.
  • R Yamamoto, T Tojo, H Tada, et al.: Prognosis of stage I non-small cell lung cancer patients with positive pleural lavage cytology. CHEST. Oct 2004.
  • 一瀬幸人:シンポジウム:進行肺癌に対す治療戦略:臨床病期IIIB期非小細胞肺癌に対する集学的治療:Bimodality treatmentと手術を含むtrimodality treat mentの第II相試験. 第104回日本外科学会. 2004年4月.
  • 一瀬幸人:ランチョンセミナー:非小細胞肺癌治療の現況と展望. 第45回臨床細胞学会総会. 2004年4月.
  • 一瀬幸人:教育講演5「非小細胞肺癌の集学的治療」:UFTを用いた術後補助化学療法. 第45回日本肺癌学会総会. 2004年4月.
  • 岡田守人、西尾 渉、阪本俊彦、他:癌転移の成立におけるConnexin26によるギャップ結合形成能の役割:癌悪性度診断とギャップ結合阻害剤による転移抑制の可能性. 第104回日本外科学会総会. 2004年4月.
  • 岡田守人、西尾 渉、阪本俊彦、他:肺癌に対する内視鏡手術の光と影. 第21回日本呼吸器外科学会総会. 2004年5月.
  • 岡田守人:ミニ開胸またはVATSによる区域切除. 第19回日本肺癌学会肺癌ワークショップ. 2004年7月.
  • 岡田守人:悪性胸膜中皮腫に対する外科的役割. 第58日本胸部外科学会総会;卒後セミナー. 2004年10月.
  • 岡田守人、西尾 渉、阪本俊彦、他:腫瘍径からみた肺癌に対する術式選択の妥当性. 第57回日本胸部外科学会総会. 2004年10月.
  • 岡田守人、西尾 渉、阪本俊彦、他:日常的な標準術式としての胸腔鏡手術;非定型な区域切除・気管支形成術はどこまで可能か. 第57回日本胸部外科学会総会. 2004年10月.
  • 岡田守人:悪性胸膜中皮腫(ポスター24例のレビュー). 第45回日本肺癌学会総会. 2004年10月.
  • 中嶋 隆、東条 尚、多田弘人、他:IIIA期非小細胞肺癌に対する術前化学療法と縦隔照射による multimodality treatment の検討. 第79回 日本肺癌学会関西支部会. 2004年2月.
  • 多田弘人、出口 寛、中嶋 隆、他:局所進行肺癌の治療戦略. 第21回日本呼吸器外科学会総会. 2004年5月.
  • 多田弘人:気道狭窄に対する治療. 日本呼吸器内視鏡学会 第16回気管支鏡セミナー. 2004年6月.
  • 塩野裕之、奥村 明之進、多田弘人、他:WHO分類を加味した胸腺上皮性腫瘍の治療指針. 第104回日本外科学会定期学術集会. 2004年4月.
  • 多田弘人:肺癌外科におけるEBM. 第45回日本肺癌学会総会. 2004年10月.
  • 太田三徳、平林弘久、多田弘人、他:縦隔浸潤型進行癌に対する治療戦略:特に心大血管浸潤肺癌に対する治療. 第104回日本外科学会定期学術集会. 2004年4月.
  • Y Ichinose.: Surgery and Adjuvant Chemotherapy: The Japanese Experience. 11th World Conference on Lung Cancer. Jul 2005.
  • J Yoshida, K Nagai, M Nishimura, et al: Limited resection trial for pulmonary ground-glass opacity nodules: Case selection based on high resolution CT. 11th World Cpnference on Lung Cancer. July 2005.
  • 岡田守人、阪本俊彦、湯木 毅、他:肺癌に対するミニ開胸を併用した胸腔鏡下手術の成績. 第105回日本外科学会総会. 2005年5月.
  • 吉田純司、永井完治、西村光世、他:肺野末梢小型肺腺癌に対する縮小手術プロトコール研究. 第105回日本外科学会定期学術集会. 2005年5月.
  • 多田弘人:肺癌におけるリンパ筋郭清の意義. 第45回日本呼吸器学会学術講演会. 2005年4月.
  • 福岡正博、國頭英夫、多田弘人:非小細胞肺癌完全切除後アジュバント化学療法は標準か?. 第45回日本呼吸器学会学術講演会. 2005年4月.
  • 福原謙二郎、多田弘人、山本良二、他: c-N1非小細胞肺癌切除例の検討. 第22回 日本呼吸器外科学会総会. 2005年6月.
  • 中嶋隆、多田弘人、加藤治文、他:原発性肺癌術後再発治療:方針の変化と予後. 第22回 日本呼吸器外科学会総会. 2005年6月.
  • M Tsuboi, T Ohira, H Kato, et al.: Surgical outcome for the subcentimeter lung cancer; Is the sublobular resection an emerging concept in this population?. 4th EACTS/ESTS Joint meeting, Barcelona, Spain, Sep 2005.
  • M Tsuboi, T Ohira, H Kato, et al.: Preoperative induction chemotherapy with weekly paclitaxel and carboplatin for clinical-stage IB-IIIA non-small cell lung cancer. 11th World Conference on Lung cancer, Barcelona, Spain, Jul 2005.
  • T Ohira, M Tsuboi, H Kato, et al.: Characterization of Gefitinib sensitive human lung cancer cell lines. 51st International college of Surgeons Japan Section, Sapporo, Japan, May 2005.
  • T Ohira, M Tsuboi, H Kato, et al.: Comparison between clinical non-small-cell lung cancer (NSCLC) samples obtained during surgery and gefitinib (IRESSA)-sensitive NSCLC cell lines characterized in vitro. 11th World Conference on Lung cancer, Barcelona, Spain, Jul 2005.
  • K Miyajima, Y Suga, H Kato, et al.: Aberrant methylation of RASSF1A in small-sized lung adenocarcinoma and its relationship to clinicopathological features. 72nd American College of Chest Physicians, Montreal, Canada, Oct 2005.
  • J Nitadori, G Ishii, H Kato, et al.: Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis. 11th IASLC World Conference on Lung Cancer, Barcelona, Spain, Jul 2005.
  • Y Suga, K Miyajima, H Kato, et al.: Detection of aberrant p16 promoter methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients using real-time PCR. 11th World Conference on Lung Cancer, Barcelona, Spain, Jul 2005.
  • Y Suga, K Miyajima, H Kato, et al.: Usefulness of detection of p16 promoter methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients using real-time PCR. 72nd American College of Chest Physicians, Montreal, Canada, Oct 2005.
  • T Mitsudomi, et al.: Clinical and biological implications of EGFR mutations lung cancer. 11th World conference on lung cancer. 2005.
  • Y Ichinose: A randomized phase III trial of adjuvant treatment for resected non-small cell lung cancer in Japan. The 21st Program Kurume University Graduate School of Medicine, Research Center for Innovative Cancer Therapy. Nov 2005.
  • Y Kawano, H Tada, et al.: Clinicopathological features and efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC) _Comparison between adenocarcinoma and non-adenocarcinoma. 11th World Conference on Lung Cancer. Jul 2005.
  • T Tojo, M R Yamamoto, H Tada, et al.: Prognosis of stage I non-small cell lung cancer patients with positive pleural lavage cytology. 11th World Conference on Lung Cancer. Jul 2005.
  • I Yoshino, Y Ichinose, et al.: Clinical characterization of node-negative non-small cell lung cancer: Results of a prospective investigation. 42nd ASCO Annual Meeting. Jun 2006.
  • I Okamoto I, Y Ichinose, et al.: EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): Results of West Japan Thoracic Oncology Group trial (WJTOG0403). 42nd ASCO Annual Meeting. Jun 2006.
  • K Goto, Y Ichinose, et al.: The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): A subgroup analysis in elderly patients (pts). 42nd ASCO Annual Meeting. Jun 2006.
  • 高坂貴行、光冨徹哉、他: 原発性肺癌切除例における上皮成長因子受容体(EGFR)遺伝子の突然変異の検索とその臨床的意義. 第105回日本外科学会総会. 2005.
  • 高坂貴行、光冨徹哉、他: 原発性肺癌切除例における上皮成長因子受容体(EGFR)遺伝子の突然変異の検索とその臨床的意義. 22回日本呼吸器外科学会総会. 2005.
  • 森正一、光富徹哉、他: 発見動機別にみた原発性肺癌切除例の検討. 第22回日本呼吸器外科学会総会. 2005.
  • 森正一、光冨徹哉、他: 結腸・直腸癌における肺転移手術症例の予後規定因子の解析. 第58回日本胸部外科学会総会. 2005.
  • 高坂貴行、光冨徹哉: 原発性肺癌切除例における上皮成長因子受容体(EGFR)遺伝子の突然変異の検索とその臨床的意義. 第64回日本癌学会学術総会. 2005.
  • 高坂貴行、坪井正博、多田弘人、他: ゲフィチニブ耐性獲得症例における二次的EGFR遺伝子変異の検討. 第43回日本癌治療学会総会. 2005.
  • 森正一、光冨徹哉、他: 原発性肺癌における開胸時洗浄細胞診の検討. 第67回日本臨床外科学会総会. 2005.
  • 森正一、光冨徹哉、他: 原発性肺腺癌切除例における喫煙の影響についての解析.第46回日本肺癌学会総会. 2005.
  • 高坂貴行、坪井正博、多田弘人、他: ゲフィチニブ耐性獲得症例における二次的EGFR遺伝子変異の検討. 第46回日本肺癌学会総会. 2005.
  • 土田正則、小池輝明、林 純一、他: 肺癌組織中核酸代謝酵素DPDmRNA発現にて層別化した肺がん術後補助療法に関する第II相臨床試験. 第22回日本呼吸器外科学会. 2005年6月.
  • 喜多秀文、広野達彦、小池輝明、他: 新潟県肺癌手術症例登録(2001-2003年). 第22回日本呼吸器外科学会. 2005年6月.
  • 大和 靖、小池輝明、吉谷克雄、他: pN2非小細胞肺癌完全切除例の予後因子に関する多施設共同研究. 第46回日本肺癌学会. 2005年11月.
  • 岡田守人: 合理的縦隔リンパ節郭清の長期成績. 第58回日本胸部外科学会総会(シンポジウム). 2005年10月.
  • 岡田守人: 早期小型肺癌が激増する時代における腫瘍径2cmでのI期分類の妥当性. 第46回日本肺癌学会総会(シンポジウム). 2005年11月.
  • 菱田智之、吉田純司、永井完治、他: 再発肺癌に対する再切除後の予後因子. 日本呼吸器外科学会総会. 2005年6月.
  • 永井完治、吉田純司、他: 2cm以下T1N0M0 NSCLCに対する手術様式. 本胸部外科学会定期学術集会. 2005年10月.
  • 清水公裕、永井完治、吉田純司、他:胸膜浸潤から考えた新病期分類の提案. 日本肺癌学会総会. 2005年11月.
  • 岡田守人: 肺がんに対するHybrid VATS -如何に多様な病態・術式に適用できるか. 第106回日本外科学会総会(パネルディスカッション). 2006年3月.
  • 吉田純司、西村光世、永井完治、他:肺野末梢小型GGO病変に対する縮小手術. 日本呼吸器外科学会総会. 2006年5月.
  • 西村光世、吉田純司、永井完治、他:パンコースト型肺がんに対する前方一後方アプローチ.日本呼吸器外科学会総会.2006年5月.
  • 多田弘人: Japanese Adjuvant Trial in Early Stage NSCLC; WJTOG0101中間解析. The 2nd WJTOG International Symposium on Lung Cancer Clinical Trial. 2006年7月.
  • S. Teramukai, K. Ochiai, H. Tada, et al.: A new prognostic index of advanced epithelial ovarian cancer (PIEPOC): A JMTO OC01-01 study.42nd Annual Meeting of the American Society of Clinical Oncology.Jun 2006.
  • M. Tsuboi, H. Kato, Y. Ichinose, et al.: the Japan Lung Cancer Research Group on Postsurgic: The influence of tumor size, histological differentiation and smoking history in patients with completely resected stage I adenocarcinoma of the lung. 42nd Annual Meeting of the American Society of Clinical Oncology.Jun 2006.
  • T. Mitsudomi, T. Kosaka, H. Endoh, et al.: Mutational analysis of the EGFR gene in lung cancer with acquired resistance to gefitinib. 42nd Annual Meeting of the American Society of Clinical Oncology.Jun 2006.
  • Y Ichinose, et al., S-1 Cooperative Study Group: Cisplatin in patients with advanced non-small-cell lung cancer. The Joint Meeting of the 3rd ISC International Conference on Cancer Therapeutics and the 11th International Symposium on Cancer Chemotherapy. December 2006.
  • 石黒太志, 片山達也, 奥田勝裕,他 :治療効果判定におけるCEAの意義. 第47回日本肺癌学会総会. 2006年12月.
  • 小野里良一, 高坂貴行, 谷田部恭, 他 :肺癌におけるLKB1/STK11遺伝子変異の検討. 第47回日本肺癌学会総会. 2006年12月.
  • 松尾恵太郎, 谷田部恭, 伊藤秀美, 他.: 非小細胞肺がん(NSCLC)における上皮成長因子受容体(EGFR)遺伝子異常の有無に対する喫煙,性の影響. 第65回日本癌学会総会. 2006年9月.
  • 井上英樹、森島敏隆、阪森優一、他:気管に発生したoncocytomaの一例.第29回 日本呼吸器内視鏡学会学術集会. 2006年6月.
  • 多田弘人: 非小細胞肺癌における術後補助化学療法のありかた.第29回 日本呼吸器内視鏡学会学術集会. 2006年6月.
  • 岩上佳史、中嶋隆、舟木壮一郎、他:Postpneumonectomy syndrome 様の症候を呈した長期左全無気肺の一手術例第80回 日本呼吸器内視鏡学会近畿支部会.2006年11月.
  • 中嶋隆、多田弘人、工藤新三、他: Carboplatin/Paclitaxelを用いた術後補助化学療法の認容性の検討(WJTOG3105-DI) . 第47回日本肺癌学会総会,2006年12月.
  • 水野鉄也、永井完治、他:StageⅠB肺腺癌における臨床病理学的予後因子と予後良好群の抽出. 第47回日本肺癌学会総会. 2006年12月
  • K Gemba, K Yamazaki, Y Ichinose, et al.: A phase I/II study of pemetrexed plus cisplatin in Japanese patients with malignant pleural mesothelioma. 43rd ASCO Annual Meeting. June 2007.
  • Y Ichinose, et al.: A randomized phase II study of 500 mg/m2 and 1,000 mg/m2 of pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer who had prior chemotherapy. 43rd ASCO Annual Meeting. June 2007.
  • T Seto, T Yamanaka, Y Ichinose, et al.: Phase I/II study of oral TS-1 and gemcitabine in elderly patients with advanced non-small cell lung cancer: Thoracic Oncology Research Group 0502. 43rd ASCO Annual Meeting. June 2007.
  • M Tsuboi, H Kato, Y Ichinose, et al., Japan Lung Cancer Research Group: Why did the gender difference influence survival in patients with completely resected stage I adenocarcinoma of the lung? 43rd ASCO Annual Meeting. June 2007.
  • S Niho, Y Ichinose, et al.: Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. 43rd ASCO Annual Meeting. June 2007.
  • 多田弘人: N2非小細胞肺癌に対する手術の意義.第47回 日本呼吸器学会学術講演会. 2007年5月.
  • 多田弘人: 気管支形成術のコツ. 第24回呼吸器外科学会総会.2007年5月.
  • 山本良二、多田弘人、高濱誠、他:原発性肺癌に対する部分切除の意義と課題.第47回 日本呼吸器学会学術講演会. 2007年5月.
  • 高濱誠、山本良二、中島隆、他: 腫瘍性病変に対する Completion pneumonectomy 症例の検討.第47回 日本呼吸器学会学術講演会. 2007年5月.
  • 多田弘人: 術前治療の問題点.第32回日本外科系連合学会学術集会. 2007年6月.
  • 高橋健司、永井完治、他:術後再発肺癌に対するgefitinibの有効性についての検討. 第24回日本呼吸器外科学会総会. 2007年5月.
  • K Aokage, G Ishii, K Nagai, et al,: Intrapulmonary metastasis in resected pathological StageⅢB non-small cell lung cancer: possible contribution of aerogenous metastasis to the favorable outcome. 12th World Confrence of Lung Cancer. Sep 2007.
  • J Yoshida, G Ishii, K Nagai, et al,: Limited resection trial for pulmonary ground-glass Opacity nodules: case selection based on high resolution computed tomography. 12th World Confrence of Lung Cancer. Sep 2007.
  • T Mizuno, G Ishii, K Nagai, et al,: Low resk subgroup identification in stage ⅠB lung adenocarcinoma patients. 12th World Confrence of Lung Cancer. Sep 2007.
  • H Tada: Advancement of surgery for non small cell lung cancer.12th World Conference on Lung Cancer. Sep 2007.
  • T Sawa, K Eguchi, T Ishigur, et al,: Japanese multidisciplinary medical care guideline for patients with lung cancer by non-profit organization of multi-institutional study group (WJTOG). 12th World Conference on Lung Cancer. Sep 2007.
  • M Takahama, R Yamamoto, R Nakajima, et al,: TCompletion pneumonectomy in lung tumor patients. ERS Annual Congress 2007.Sep 2007.
  • 吉田純司:肺野末梢の小型graund-glass opacity病変の診断.第32回日本外科系連合学会学術集会.2007年6月.
  • 小鹿雅和、永井完治:p-N2肺癌切除症例の予後.第48回日本肺癌学会総会.2007年11月.
  • 高橋健司、永井完治:術後再発肺腺癌症例に対するgefitinibの治療効果についての検討.第108回日本外科学会定期学術集会.ワークショップ.2008年5月.
  • 菱田智之、永井完治:cN2/pN2非小細胞肺癌に対するpromary surgeryの治療成績-内科的治療との比較-.第25回日本外科学会定期学術集会.2008年5月.
  • 宮田俊男、中嶋隆、高濱誠、他: 肺癌副腎転移切除6例の検討. 第86回日本肺癌学会関西支部会. 2007年7月.
  • 中嶋隆、高濱誠、宮田俊男、他: Ⅲ期非小細胞肺癌に対する照射野を限局した術前化学放射線療法の治療成績.第48回日本肺癌学会総会.2007年11月.
  • 高濱 誠、山本良二、中嶋 隆、他: 悪性気道狭窄に対する硬性鏡下ステント留置症例の検討. 第48回日本肺癌学会総会.2007年11月.
  • 宮田俊男、山本良二、高濱 誠、他: 縦隔腫瘍との鑑別が困難であった硬化性縦隔炎の1例. 第87回日本肺癌学会関西支部会.2008年2月.
  • 武田晃司、駄賀晴子、清田秀美、他: 肺癌患者はセカンドオピニオンに何を期待しているのか . 第87回日本肺癌学会関西支部会.2008年2月.
  • 高濱誠、山本良二、中嶋隆、他: 甲状腺癌気管浸潤切除術後に発症した気管狭窄に対する気管管状切除術総会.第25回日本呼吸器外科学会総会.2008年5月.
  • 中嶋隆、山本良二、高濱誠、他: 気管・気管支ステント再留置術の安全性・有効性の検討.第25回日本呼吸器外科学会総会.2008年5月.
  • 高濱誠、山本良二、中嶋隆、他: 慢性血液透析患者に対する肺癌手術例の検討. 第108回日本外科学会定期学術集会. 2008年5月.
  • Henri G.Colt、Thomas G Sutedja、石田敦子、他: インターベンショナル・ブロンコロジー. 第31回日本呼吸器内視鏡学会学術集会.2008年6月.
  • 中嶋隆、山本良二、高濱誠、他: 悪性疾患気道狭窄症例に対する積極的気道管理-複数回の気道拡張術の検討-. 第31回日本呼吸器内視鏡学会学術集会.2008年6月.
  • 泉信博、多田弘人、山本良二、他: 診断に難渋した肺MOLT lymphoma の1例.第88回日本肺癌学会関西支部会.2008年7月.

4. 総説・解説

  • H Kato, K Furukawa, N Ikeda, et al.: Phototherapy for lung cancer in 2000: the Japanese experience. International Forum Advances in Airway Endoscopy. Nov 2000.
  • H Kato: Novel Methods for Treatment of Early Lung Cancer. IASLC 3rd International Conference on Prevention and Early Detection of Lung Cancer. Aug 2001.
  • H Kato, M Tsuboi: Early Lung Cancer: World Ongoing Trials, Japan, Screening of Lung, Cancer, early localization and treatent. International Symposium on Lung Cancer. Sep 2001.
  • H Kato, M Tsuboi: Adjuvant Therapy for Early Stage NSCLC. The Second International Chicago Symposium on Malignancies of the Chest and Head & Neck. Oct 2001.
  • 一瀬幸人、加藤治文、小池輝明、他:ワークショップ「外科におけるrandomized controlled trial」:Japan Clinical Oncology Group(JCOG)肺がん外科グループにおけるrandomized controlled trial. 第102回日本外科学会総会. 2002年4月.
  • K Suzuki.: Indication of surgery for small cell lung cancer. IASCO workshop, 2002.
  • 鈴木健司:悪性胸膜中皮腫に対する外科治療. 第44回日本肺癌学会総会. 教育講演, 2002年.
  • H Kato.: Early localization of sputum detected lung cancer, The 11th International conference on Screening for Lung Cancer. Oct 2004.
  • H Kato.: Adjuvant chemotherapy with UFT for resected NSCLC, IASLC Workshop. Oct 2004
  • H Kato.: The postoperative adjuvant trials with UFI for p-stage 1 non-small cell lung cancer, The 42nd Annual Meeting of Japan Society of Clinical Oncology. Oct 2004.
  • K Suzuki.: Management of CT detected lung nodules. Hot topics. 2005 11th World Conference on Lung Cancer, 2005.
  • H Kato. History of PDT. 16th World Congress of the International Society for Laser Surgery and Medicine, Tokyo, Sep 2005.
  • N Ikeda, H Honda, H Kato, et al.: Recent advances in endoscopic early detection of bronchial lesions. 11th World Conference on Lung Cancer, Barcelona, Jul 2005.
  • M Tsuboi, H Kato: The new technologies for the diagnosis and therapy of lung cancer. 14th Panhellenic Congress on Thoracic Diseases, Thessaloniki, Greece, Dec 2005.
  • H Asamura, M Tsuboi, H Kato: Japanese Clinical Trials; ongoing & closed. 18th annual meeting of General Thoracic Surgical Club, Florida, USA, Mar 2005.
  • 加藤治文.: 末梢型小型肺癌の診断と治療. 第67回日本臨床外科学会総会、2005年11月.
  • 坪井正博, 加藤治文.: 非小細胞肺癌手術補助療法の戦略;術前化学療法の臨床試験と今後のstudy designを中心に. 第22回日本呼吸器外科学会総会シンポジウム. 2005年6月.
  • 坪井正博, 加藤治文.: 非小細胞肺癌術後の補助化学療法は標準治療となったか;「術後病期I期症例に対する治療」. 第43回日本癌治療学会総会ワークショップ. 2005年10月.
  • 坪井正博, 加藤治文.: 術後アジュバント治療におけるEGF受容体チロシン・キナーゼ阻害剤. 第20回日本肺癌学会ワークショップ. 2005年7月.
  • 坪井正博, 加藤治文.: IB-III期非小細胞肺癌に対する術前化学療法の取組み. 第46回日本肺癌学会総会シンポジウム. 2005年11月.
  • 岡田守人: Hybrid VATS. 第46回日本肺癌学会総会(イーブニングセミナー). 2005年11月.
  • 岡田守人: 区域切除の実際 -Policy & Skill. 第22回日本呼吸器外科学会総会(ランチョンセミナー). 2005年6月.
  • 光冨徹哉: EGF受容体変異と薬剤感受性. 第20回日本肺癌学会ワークショップ. 2005.
  • 光冨徹哉: 肺癌の分子生物学とその臨床応用. 第58回日本胸部外科学会総会. 2005.
  • 光冨徹哉: 肺がんにおけるEGFR遺伝子変異と個別化医療. 第64回日本癌学会総会. 2005.
  • 光冨徹哉: 肺癌におけるEGFR 遺伝子変異と分子標的治療. 第43回日本癌治療学会総会. 2005.
  • 多田弘人: 特別講演:非小細胞肺癌の術前・術後治療について. 静岡県呼吸器外科医会 第16回集談会. 2005年1月.
  • 多田弘人: シンポジウム:肺癌におけるリンパ筋郭清の意義. 第45回日本呼吸器学会学術講演会. 2005年4月.
  • 福岡正博、國頭英夫、多田弘人: プロ・コンセッション:非小細胞肺癌完全切除後アジュバント化学療法は標準か?. 第45回日本呼吸器学会学術講演会. 2005年4月.
  • 吉田純司: 病期IB-II非小細胞肺癌に対する術前化学療法の展望.  日本呼吸器外科学会総会. 2006年5月.
  • 岡田守人: 縮小手術. 第32回日本肺癌学会肺癌診断会(シンポジウム指定発表). 2006年6月.
  • 岡田守人: 胸膜中皮腫における胸腔鏡の役割. 第29回日本呼吸器内視鏡学会学術集会(シンポジウム). 2006年6月.
  • 岡田守人: 胸間質性肺炎患者の肺癌手術. 第46回日本呼吸器学会学術講演会(呼吸器外科学会との共同企画―シンポジウム指定講演). 2006年6月.
  • 岡田守人: 悪性胸膜中皮腫に対する外科治療とその成績. 第23回日本呼吸器外科学会総会(ワークショップ). 2006年5月.
  • 岡田守人: 肺癌手術の治療成績. 第23回日本呼吸器外科学会総会(ワークショップ). 2006年5月.
  • 岡田守人: 気管支形成・血管吻合における吻合・縫合のテクニック. 第23回日本呼吸器外科学会総会(ランチョンセミナー). 2006年5月.
  • 多田弘人: 分子標的薬を用いた非小細胞肺癌に対する補助化学療法の可能性. 第46回日本呼吸器学会学術講演会. 2006年6月.
  • H Kato: The Japanese Photodynamic Association and present status of PDT in Japan, 6th Annual congress of the Korean Photodynamic Associatio,Auguest.2006.
  • H Kato: The role of molecular markers, The 15th International conference on Screening for Lung Cancer,October. 2006.
  • T Mitsudomi :EGFR mutations and predictive markers for EGFR TKI therapy in treatment of non-small cell lung cancer. Taiwan Cooperative Oncology Group Institute of Cancer Research.,December.2006.
  • T Mitsudomi :The role of EGFR -mutations in Asian population. Molecular Targeted Therapies in Lung Cancer,November.2006.
  • T Mitsudomi :Biologic and Clinical Implications of EGFR Mutations in lung cancer 32nd Annual Meeting of Korean Cancer Asssociation. June.2006.
  • T Mitsudomi, T Kosaka, H Endoh, et al.: Mutational analysis of the EGFR gene in lung cancer with acquired resistance to geftinib. 42nd ASCO annual meeting; Poster Discussion,June.2006.
  • M Varella-Garcia, T Mitsudomi, Y Yatabe, et al.: EGFR genomic gain in Japanese nn-small cell lung cancer patients treated with gefitinib. 42nd ASCO annual meeting; General Poster,June.2006.
  • 光冨徹哉. :Current topics of small molecules targeted to EGFR in lung cancer. The Joint Meeting of The 3rd ISC International Conference on Cancer Therapeutics andm The 11th International Symposium on Cancer Chemotherapy.,December.2006.
  • 加藤治文:喫煙習慣と関連がん(生活習慣曝露):診断と治療について, 平成18年度日本癌学会シンポジウム 2006年7月.
  • 加藤治文:「日本(アジア)人にのみ効く薬(制癌剤)とは何か」:「個別治療に向けて」の感触, 日本癌病態治療研究会秋季学術講演会 2006年11月.
  • 光冨徹哉. :EGFRをめぐる最新情報. 第4回日本臨床腫瘍学会総会. 2006年3月.
  • 光冨徹哉.: 肺癌の分子標的治療-ゲフィチニブの感受性予測因子. 第39回制癌剤適応研究会. 2006年3月.
  • 星川 康、桜田 晃、近藤 丘:肺癌診療ガイドラインの利用状況と評価-2003年版の使用状況に関するアンケート集計結果より-.第47回日本肺癌学会総会.2006年12月.
  • H Kato : The present and future photodynamic diagnosis and therapy in pneumology, 11th World Congress of the International Photodynamic Association,March. 2007.
  • 加藤治文:非小細胞肺がんの補助化学療法についての動向、第21回冬季札幌がんセミナー 2007年2月.
  • 遠藤千顕、近藤 丘:肺癌外科療法のガイドライン. 第48回日本呼吸器学会学術講演会. 2008 年 6 月.